K. Kleist

The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity

D. Logan, S. Dillon, M. Maurer, 2022, Nature Communications.

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Inflammatory Arthritis.

S. Dillon, S. Mudri, S. Peng, 2023, Arthritis & rheumatology.

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

S. Dillon, S. Mudri, S. Peng, 2023, Arthritis & rheumatology.

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

S. Dillon, S. Mudri, S. Peng, 2023 .